# Empatica

> Empatica develops medical wearables, algorithms and cloud software for remote health monitoring. Its EpiMonitor system detects patterns associated with generalized tonic-clonic seizures and alerts caregivers; its research platform collects physiological data for academic studies and clinical trials. Following its acquisition of PKG Health, it also provides Parkinson’s monitoring for clinicians.

- **Founded:** 2011
- **Headquarters:** Cambridge, United States
- **Founders:** Matteo Lai (Chief Executive Officer and co-founder), Simone Tognetti (Chief Technology Officer and co-founder), Rosalind Picard (Chief Scientist and co-founder), Maurizio Garbarino (Chief Software Architect and co-founder)
- **Products:** Embrace / Embrace2, Empatica Health Monitoring Platform and EmbracePlus, EpiMonitor, EmbraceMini, eCOA within Care App
- **Notable:** Embrace received FDA 510(k) clearance on January 26, 2018 (K172935)., Empatica Health Monitoring Platform FDA clearance announced November 2022., EmbraceMini sleep-monitoring clearance announced January 8, 2026.

## Products & services

- **Embrace / Embrace2** — Earlier wrist-worn seizure monitoring products. Embrace first received FDA clearance in January 2018; Embrace2 is no longer sold, with support continuing for existing users.
- **Empatica Health Monitoring Platform and EmbracePlus** — Medical wearable, mobile apps, cloud infrastructure and portals for continuous physiological data collection in research, clinical trials and remote monitoring; initial platform FDA clearance announced in November 2022.
- **EpiMonitor** — EmbracePlus wearable and smartphone app for detecting patterns associated with generalized tonic-clonic seizures and notifying designated caregivers; for adults and children aged six and older, with a US prescription requirement. Device listed at US$399; US Basic subscription US$17.40 monthly after April 20, 2026.
- **EmbraceMini** — 15-gram wearable with accelerometer, gyroscope, magnetometer and ambient-light sensor for actigraphy and movement monitoring; launched June 2025, sleep-monitoring clearance announced January 2026.
- **eCOA within Care App** — Electronic clinical outcome assessment capability adds functional assessments and patient-reported information alongside wearable measures.
- **Parkinson’s Monitoring with PKG measures** — EmbraceMini, PKG Monitor app, cloud processing and clinician reporting support objective monitoring of motor symptoms and treatment response. European certification announced January 2026 and FDA clearance August 2026.
- **Cloud API for Clinical Trials** — Cloud integration lets study teams access wearable data and manage participants through existing research systems.

## Achievements

- Embrace received FDA 510(k) clearance on January 26, 2018 (K172935).
- Empatica Health Monitoring Platform FDA clearance announced November 2022.
- EmbraceMini sleep-monitoring clearance announced January 8, 2026.
- Parkinson’s monitoring CE MDR certification announced January 30, 2026; FDA clearance announced August 19, 2026.
- Company reports twelve FDA clearances as of August 2026.

## Latest updates

- **2026-09** — EmbraceMini became available for the Academic & Basic Research Plan on September 23.
- **2026-08** — Empatica announced FDA clearance for its Parkinson’s monitoring platform on August 19.
- **2026-04** — New EpiMonitor subscription prices took effect April 20; US Basic monthly price became US$17.40.
- **2026-01** — EmbraceMini sleep-monitoring FDA clearance and Parkinson’s CE MDR certification were announced.

## Links

- Website: https://www.empatica.com/
- LinkedIn: https://www.linkedin.com/company/empatica
- Twitter/X: https://x.com/empatica
- GitHub: https://github.com/empatica
- YouTube: https://www.youtube.com/empatica
- Instagram: https://www.instagram.com/empatica_wearables/
- Facebook: https://www.facebook.com/empatica

---

Profile page: https://yespress.io/empatica
Published by YesPress — https://yespress.io
Last updated: 2026-10-04